AbbVie Inc. (ABBV) and ADARx Pharmaceuticals, Wednesday announced a collaboration and license option agreement to develop small interfering RNA or siRNA therapeutics across multiple disease areas including neuroscience, immunology and oncology.
As per the terms of the deal, ADARx will receive a $335 million upfront payment and several billion dollars in additional contingent payments.
The collaboration will integrate ADARx's RNA discovery expertise and proprietary siRNA technology with AbbVie's expertise in antibody engineering, antibody drug conjugates, tissue delivery approaches and commercialization.
In the pre-market hours, AbbVie's stock is trading at $186.51, down 0.79 percent on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.